Ryvu is a biopharmaceutical company developing small molecule therapies that address clinical limitations of current treatments in oncology.
Ryvu is a biopharmaceutical company developing small-molecule therapies that address the clinical limitations of current treatments in oncology.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 30, 2022 | Post-IPO Equity | €20M | 1 | BioNTech | — | Detail |
Aug 17, 2022 | Post-IPO Debt | €22M | 1 | European Investment Bank | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
BioNTech | Yes | Post-IPO Equity |
European Investment Bank | Yes | Post-IPO Debt |